Is it necessary to test PD-L1 before using PD-1/PD-L1 inhibitors? Is it possible to “blindly” try without testing?

According to the drug insert, Pembrolizumab must be tested for PD-L1 status prior to use in either first- or second-line therapy; Nivolumab, Atezolizumab for second-line use, and Durvalumab for consolidation therapy in patients with stage III NSCLC without progression after concurrent radiotherapy do not require testing for PD-L1 status. status.

Co-reviewed by Dr. Wang Zhen, Deputy Chief Physician, Guangdong Provincial People’s Hospital, Guangdong Lung Cancer Institute Xiaoxiao Peng